Skip to main content

Advertisement

SpringerLink
Log in

Dapagliflozin as a cause of acute tubular necrosis with heavy consequences: a case report

  • Case Report
  • Published:
CEN Case Reports Aims and scope Submit manuscript

Abstract

A 50-year-old man with type II diabetes, hypertension and dyslipidemia, presented with non-oliguric acute kidney injury (AKI) and anemia. Renal biopsy showed acute tubular necrosis (ATN) with extensive cytoplasmic vacuolization and areas of tubulitis. These findings were ultimately attributed to dapagliflozin, which he started 3 months earlier due to poor glycemic control. ATN with similar microscopic findings has been described with larger doses of dapagliflozin in non-clinical trials. Our patient was started on dialysis and remained dialysis-dependent for 4 weeks while his renal function improved gradually thereafter. Sixteen months after initial presentation he is being followed as an outpatient with chronic kidney disease (CKD) stage 3a. Dapagliflozin belongs to a novel class of antidiabetic drugs for which clinical trials show great beneficial effects on cardiovascular outcomes and glycemic control and as with many new drugs, their safety profile is being constantly revised. We report the first biopsy-proven ATN caused by dapagliflozin. Great caution together with continuous monitoring of renal function is advised when implementing SGLT-2 inhibitors in clinical practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. CANVAS—CANagliflozin cardio Vascular Assessment Study (CANVAS). https://clinicaltrials.gov/ct2/show/NCT01032629?term=NCT01989754&rank=2.

  2. Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events (DECLARE-TIMI58). https://clinicaltrials.gov/ct2/show/NCT01730534?term=NCT01730534&rank=1.

  3. Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004). https://clinicaltrials.gov/ct2/show/NCT01986881?term=NCT01986881&rank=1.

  4. Zinman B, Wanner C, Lachin JM, et al. for the EMPA-REG OUTCOME investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.

    Article  CAS  PubMed  Google Scholar 

  5. Faillie JL. Pharmacological aspects of the safety of gliflozins. Pharmacol Res. 2016. https://doi.org/10.1016/j.phrs.2016.07.001.

    PubMed  Google Scholar 

  6. Wu JH, Foote C, Blomster J, et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2016;4(5):411–9.

    Article  CAS  PubMed  Google Scholar 

  7. Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;159(4):262 – 74.

    Article  PubMed  Google Scholar 

  8. Wanner C, Inzucchi SE, Lachin JM, et al. EMPA-REG OUTCOME investigators. Empagliflozin and progression of kidney disease in Type 2 Diabetes. N Engl J Med. 2016;375(4):323 – 34.

    Article  CAS  PubMed  Google Scholar 

  9. DeFronzo RA, Norton L, Abdul-Ghani M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat Rev Nephrol. 2017;13(1):11–26.

    Article  CAS  PubMed  Google Scholar 

  10. FDA Drug Safety Communication: FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR) [06-14-2016] http://www.fda.gov/Drugs/DrugSafety/ucm505860.htm.

  11. Hahn K, Ejaz AA, Kanbay M, Lanaspa MA, Johnson RJ. Acute kidney injury from SGLT2 inhibitors: potential mechanisms. Nat Rev Nephrol. 2016;12(12):711–2.

    Article  CAS  PubMed  Google Scholar 

  12. Agati D’, Jennette VD, Silva JC. FG. Non-neoplastic kidney diseases. Silver Spring: ARP Press; 2005. pp. 517–31.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nephrology, General Hospital of Chania, Meletiou Metaxaki 25, 73131, Chania, Crete, Greece

    Christos Pleros, Elisavet Stamataki, Antonia Papadaki, Nikolaos Damianakis, Rafaela Poulidaki & Ioannis Tzanakis

  2. Division of Pathology, Athens Medical School, National and Kapodistrian University of Athens, Athens, Greece

    Charikleia Gakiopoulou

Authors
  1. Christos Pleros
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elisavet Stamataki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Antonia Papadaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nikolaos Damianakis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rafaela Poulidaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Charikleia Gakiopoulou
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ioannis Tzanakis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christos Pleros.

Ethics declarations

Conflict of interest

The authors have declared that no conflict of interest exists.

Research involving human participants and/or animals

This article does not contain any studies with human participants performed by any of the authors.

Informed consent

Informed consent was obtained from all individual participants included in the study.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pleros, C., Stamataki, E., Papadaki, A. et al. Dapagliflozin as a cause of acute tubular necrosis with heavy consequences: a case report. CEN Case Rep 7, 17–20 (2018). https://doi.org/10.1007/s13730-017-0283-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13730-017-0283-0

Keywords

Search

Navigation